February 12, 2018 / 10:08 AM / 3 months ago

Norway to buy Biogen's Spinraza medicine - broadcaster NRK

OSLO (Reuters) - Norwegian authorities will buy the rare-disease treatment Spinraza for patients from U.S. drugmaker Biogen Inc(BIIB.O) at a cost of 7 million Norwegian crowns (635,883.95 pounds) per year per patient, public broadcaster NRK reported on Monday.

A sign marks a Biogen facility in Cambridge, Massachusetts, U.S. January 26, 2017. REUTERS/Brian Snyder

Spinraza treats the rare, often fatal disease spinal muscular atrophy (SMA). Norwegian authorities will cover the costs for minors only.

    Reporting by Gwladys Fouche, editing by Terje Solsvik

    0 : 0
    • narrow-browser-and-phone
    • medium-browser-and-portrait-tablet
    • landscape-tablet
    • medium-wide-browser
    • wide-browser-and-larger
    • medium-browser-and-landscape-tablet
    • medium-wide-browser-and-larger
    • above-phone
    • portrait-tablet-and-above
    • above-portrait-tablet
    • landscape-tablet-and-above
    • landscape-tablet-and-medium-wide-browser
    • portrait-tablet-and-below
    • landscape-tablet-and-below